AtaiBeckley Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
46.3%projected annual EPS growth
Analyst Coverage
8analysts covering
FY Revenue (est.)
$3.5Mnext fiscal year
FY EPS (est.)
-$0.43next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
BPL-003 Phase 3 ReConnection Program Initiation QuarterlyTarget: Initiation of two parallel Phase 3 clinical trials for treatment-resistant depression (TRD)
VLS-01 Phase 2b Topline Data Readout QuarterlyTarget: Release of topline efficacy and safety data for VLS-01 (buccal film DMT) in TRD
Cash Runway Quarterly209.9MTarget: Sufficient liquidity to fund operations into early 2029
Watch Items
- BPL-003 Phase 3 Patient Enrollment and Site ActivationTrigger: Delays in site activation or slower-than-expected patient recruitment for the ReConnection programAction: Re-evaluate clinical trial operations, expand geographic footprint of trial sites, or adjust projected timeline for topline data
- VLS-01 Phase 2b Clinical Efficacy and Tolerability ProfileTrigger: Failure to meet primary efficacy endpoints or emergence of adverse safety signals in the buccal film DMT trialAction: Assess pipeline prioritization, reallocate capital to BPL-003, and review formulation optimization strategies
Research as of 20 Jun 2026